BPH Global Ltd
ASX:BP8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BPH Global Ltd
Total Liabilities & Equity
BPH Global Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BPH Global Ltd
ASX:BP8
|
Total Liabilities & Equity
AU$1.2m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-30%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Liabilities & Equity
$782.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
0%
|
|
|
CSL Ltd
ASX:CSL
|
Total Liabilities & Equity
$37.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Liabilities & Equity
AU$24.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Liabilities & Equity
AU$1.2B
|
CAGR 3-Years
66%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Liabilities & Equity
AU$159.1m
|
CAGR 3-Years
71%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
BPH Global Ltd
Glance View
BPH Global Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Sydney, New South Wales. The company went IPO on 2000-06-13. BPH Global Ltd, formerly Stemcell United Limited, is a plant-focused biotechnology company. The firm is focused on producing foods and products that deliver Traditional Chinese Medicine-based health outcomes. The firm focuses on the research and development, production and commercialization of plant-based products, including seaweed and sea plants to produce sustainable plant-based protein foods and nutraceutical and pharmaceutical ingredients (including cannabidiol (CBD) extracted from Hemp) for utilization in the food, nutrition, healthcare, health supplements, cosmetics, and personal care industries. Its principal business focus is on Singapore, Australia, Southeast Asia, and Chinese markets. Its subsidiaries include Stemcell United Pte Ltd, Stemcell Essential Pte Ltd, SCU (HK) Ltd, Yunnan Huafang Industrial Hemp Co Ltd, SCU Southeast Asia Sdn Bhd, SCU Lab Pty Ltd, Shenzhen Lantene Dingzhi Biotechnology Co Ltd, Hainan SCU Biotechnology Co Ltd, and SCU-RY Farm Pte Ltd.
See Also
What is BPH Global Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
1.2m
AUD
Based on the financial report for Dec 31, 2025, BPH Global Ltd's Total Liabilities & Equity amounts to 1.2m AUD.
What is BPH Global Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-30%
Over the last year, the Total Liabilities & Equity growth was 277%. The average annual Total Liabilities & Equity growth rates for BPH Global Ltd have been -17% over the past three years , -24% over the past five years , and -30% over the past ten years .
